Changes in antimicrobial resistance of clinical isolates ofAcinetobacter baumanniigroup isolated in Greece, 2010‐2015. Issue 4 (April 2018)

• Record Type: Journal Article
• Authors: Dafopoulou, K.; Tsakris, A.; Pournaras, S.
• Is Part Of: Journal of medical microbiology. Volume 67:Issue 4(2018)
• Publication Date: 2018-04
• Subjects: resistance rates -- antimicrobials -- cumulative susceptibilities -- carbapenems -- trimethoprim/sulfamethoxazole; Medical microbiology -- Periodicals; 616.9041
• DOI: 10.1099/jmm.0.000708
• Languages: English
• ISSNs: 0022-2615

Abstract

Abstract : N/A: In recent years, hospitals in southeastern Europe have faced dramatically high rates of antibiotic‐resistant Acinetobacter baumannii . We analysed the evolution of resistance among clinical isolates of A. baumannii group obtained from nine tertiary hospitals throughout Greece over 6 years (2010‐2015). Identification and antimicrobial susceptibility testing were performed using Vitek 2 or Microscan walkaway automated systems. Between 2010 and 2015, resistance to ampicillin/sulbactam increased from 46.2 to 88.2 % ( P =0.021), resistance to gentamicin increased from 69.3 to 86.4 % ( P =0.014) and resistance to tobramycin increased from 59.8 to 76.8 % ( P= 0.011). Imipenem resistance rates were consistently very high, ranging from 90.3 % in 2010 to 94.5 % in 2015 ( P =0.198), while meropenem resistance rates increased from 82.6 % in 2010 to 94.8 % in 2015 ( P =0.006). Resistance rates to trimethoprim/sulfamethoxazole showed a remarkable decreasing trend, declining from 90.2 % in 2010 to 69.1 % in 2015 ( P =0.035). These evolutions render the treatment of A. baumannii infections particularly challenging and underline the need for enhanced infection control measures.